Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BEAM, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Ristoglogene Autogetemcel (BEAM-101) | Sickle Cell Disease | Phase 1/2 · NCT05456880 | Active not recruiting |
| Allogeneic Anti-CD7 CAR-T Cells BEAM-201 | Lymphoblastic Lymphoma | Phase 1/2 · NCT05885464 | Active not recruiting |
| BEAM-301: Single dose of BEAM-301 administered… | Glycogen Storage Disease Type Ia | Phase 1/2 · NCT06735755 | Recruiting |
| BEAM-302 | Alpha 1-Antitrypsin Deficiency | Phase 1/2 · NCT06389877 | Recruiting |
| Allogeneic Anti-CD7 CAR T Cells | T-Cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 · NCT06934382 | Active not recruiting |
| BEAM-103 | Healthy Subjects | Phase 1 · NCT07304791 | Recruiting |
| Long-Term Follow-up Study of patients who… | Hemoglobinopathy | N/A · NCT07373639 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BEAM holds $1B in cash and short-term investments (as of Sep 30, 2026) and burns about $88.4M/quarter from operations, an estimated runway of 35.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BEAM files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| ARK Investment Management LLC | Institution (13G, 5%+) | 11,805,372 | 11.41% | 2026-09-30 |
| Farallon Capital Management, L.L.C. | Institution (13G, 5%+) | 10,282,210 | 9.93% | 2026-06-30 |
| Dapice Joshua J. | 5%+ holder (13G) | 10,141,856 | 9.80% | 2025-12-31 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 5,228,529 | 5.05% | 2025-12-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 5,122,475 | 4.95% | 2026-03-31 |
| FMR LLC 10% owner |
Insider | 1,695,828 | 1.64% | 2026-06-25 |
| John M. Evans CEO, Director · +335,813 options |
Insider | 1,150,205 | 1.11% | 2026-10-15 |
| Giuseppe Ciaramella President · +534,259 options |
Insider | 253,911 | 0.25% | 2026-09-24 |
| Christine Bellon Chief Legal Officer · +40,000 options |
Insider | 109,711 | 0.11% | 2026-04-01 |
| Sravan Kumar Emany Chief Financial Officer · +63,500 options |
Insider | 105,456 | 0.10% | 2026-03-31 |
| Amy Simon Chief Medical Officer · +88,500 options |
Insider | 85,696 | 0.08% | 2026-07-27 |
| Bethany J Cavanagh SVP, Finance and Treasurer · +40,000 options |
Insider | 50,984 | 0.05% | 2026-10-01 |
Share count 103,495,644 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BEAM and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →